rolipram has been researched along with Cancer of Pituitary in 2 studies
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishiyama, S | 1 |
| Okudaira, M | 1 |
| Saito, N | 1 |
| Gordeladze, JO | 1 |
2 other studies available for rolipram and Cancer of Pituitary
| Article | Year |
|---|---|
Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats.
Topics: Adenocarcinoma; Animals; Carcinogenicity Tests; Estradiol; Estrous Cycle; Female; Male; Mammary Neop | 2006 |
The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenoma; Adenylyl Cyclases; Animals; Colforsin; Cyclic AMP; Enz | 1990 |